Phase 4 N=182 The Effects of Dexamethasone on Low Dose Interscalene Brachial Plexus Block
Shoulder Surgery · Nerve Block
Primary: Duration of Sensory Block — 521; 566 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=1,991 Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Time to Inadequate Glycaemic Control — 108.9; 64.9 Weeks — p=<.0001
Phase 4 N=100 Subconjunctival Versus Direct Mitomycin C in Trabeculectomy
Open Angle Glaucoma
Primary: Percentage of Participants Achieving Intraocular Pressure Reduction Thresholds — 21; 21; 1; 3 Participants
Phase 4 N=96 Effect of Vitamin D Supplementation on Bone Turnover Markers During PrEP in MSM
Patient Adherence
Primary: Change in Total Procollagen Type 1 N-terminal Propeptide (a Marker of Bone Formation) [P1NP] Levels — -27.6; -2.5 pg/mL
Phase 4 N=16 HIV Persistence and Viral Reservoirs
HIV · HIV Infections
Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio
Phase 4 N=47 Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules
Cystic Fibrosis
Primary: Number of Participants With Critical Use Errors and Close Calls Associated With the Simulated Inhalation of One Dose Using TOBI Podhaler — 4 Participants
Phase 4 N=599 To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
Kidney Transplantation
Primary: Percentage of Participants Who Were Positive for de Novo DSA (dnDSA) or Immune Activation (IA) Occurrence — 35.6; 34.4 percentage of participants — p=0.5777
Phase 4 N=26 Clinical Trial Comparing Effectiveness of Buffered Versus Unbuffered Local Anesthetic in Children Ages 10-12 Years
Anesthesia, Local · Pain
Primary: Mean Pain Scores Following Injection — 3.0; 3.3 score on a scale — p=0.38
Phase 4 N=281 Buprenorphine to Improve HIV Care Engagement and Outcomes
HIV · Substance Related Disorders
Primary: Number of Participants With HIV Viral Suppression — 97; 92; 74; 99 Participants
Phase 4 N=27 The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics
Chronic Gout · Hyperuricemia
Primary: Oxypurinol Renal Clearance — 1.9; 1.4; 1.6 L/hr
Phase 4 N=42 Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen
Aging-related Inflammation in HIV-infected Patients
Primary: Changes in the Inflammatory Marker IL-6 — 42.5; 40.0; 39.3; 41.1 pg/mL
Phase 4 N=14 Botulinum Toxin Type A Injection After Topical Anesthesia Versus Petrolatum Ointment
Forehead Rhytides · Forehead Wrinkles
Primary: Eyebrow Excursion — 10.57; 10.57 millimeters
Phase 4 N=10 Minocycline for Treatment of Posttraumatic Stress Disorder in Veterans
PTSD
Primary: PTSD Symptom Severity — 31.5; 23 score on a scale
Phase 4 N=210 Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA
Spondylitis, Ankylosing
Primary: Percentage of Participants Who Experienced Flare Within 40 Weeks Following Withdrawal of 24 Weeks of Etanercept Treatment — 74.8 percentage of participants
Phase 4 N=14 The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: The Magnitude of Change in Isokinetic Power (Performance Fatigue, PF) Associated With Stiolto Respimat Compared With Placebo Respimat at Isotime During Constant Work…